Literature DB >> 10029454

The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features.

R E Felgar1, K E Salhany, W R Macon, G G Pietra, M C Kinney.   

Abstract

Anaplastic large cell lymphomas (ALCL) are a heterogeneous group of CD30+ large cell lymphomas; the most characteristic type have a T or null cell phenotype, often express epithelial membrane antigen (EMA) and cytolytic lymphocyte markers, and often possess a nonrandom t(2;5)(p23;q35) chromosomal translocation. We studied 22 (19 T, 1 null, 2 B cell) ALCL, including four primary cutaneous ALCL (PC-ALCL), for the expression of TIA-1, the cytotoxic T lymphocyte (CTL) or natural killer (NK) cell-associated antigens CD4, CD8, betaF1, TCRdelta1, CD56, and CD57, the ALCL-associated antigens p80 and EMA, and the Hodgkin's disease-associated marker CD15 to better define the relationship of these markers to histological subtype, primary site, and patient clinical characteristics. TIA-1 expression was seen in 12 of 20 (60%) T or null cell ALCLs with a cytoplasmic, granular distribution. Ultrastructural studies showed cytotoxic-type granules (dense core, multivesicular, and intermediate types) with TIA-1 localized to granules on immunogold labeling. TIA-1 staining strongly correlated with young patient age (< or = 32 years, P < .05) and EMA expression (P < .05). Excluding the four PC-ALCL cases, TIA-1 staining also correlated with p80 expression (P < .05) in all of the T cell cases. Three CD15+ cases were TIA-1-. TIA-1 expression in T or null cell ALCL was seen in all morphological subtypes (2 of 2 small cell variant, 3 of 4 monomorphic variant, and 7 of 14 pleomorphic variant) and primary tumor sites (6 of 14 nodal, 2 of 4 primary cutaneous, 2 of 2 bone, and 2 of 2 soft tissue). TIA-1+ granules were seen in all subsets: 5 of 6 CD4+, 1 of 2 CD8+, 4 of 8 CD56+, and 1 of 2 CD57+ ALCL. Of note, 4 of 10 T or null cell ALCL expressed gammadelta T-cell receptors (TCR), whereas only 1 of 10 T or null cell ALCL was alphabeta TCR+; TCR were not detected in five cases. TIA-1 was expressed by 3 of 4 gammadelta TCR+ ALCL and 1 of 1 alphabeta TCR+ ALCL. These data support a cytotoxic lymphocyte phenotype in most T or null cell ALCL and suggest that some T cell ALCL are derived from cytolytic CD4+ T cells, gammadelta T cells, or NK-like (CD56+ or CD57+) T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029454     DOI: 10.1016/s0046-8177(99)90281-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Authors:  R L ten Berge; F G Snijdewint; S von Mensdorff-Pouilly; R J Poort-Keesom; J J Oudejans; J W Meijer; R Willemze; J Hilgers; C J Meijer
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

2.  PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.

Authors:  Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon
Journal:  Mod Pathol       Date:  2010-01-29       Impact factor: 7.842

3.  Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

Authors:  Nathan R West; Katy Milne; Pauline T Truong; Nicol Macpherson; Brad H Nelson; Peter H Watson
Journal:  Breast Cancer Res       Date:  2011-12-08       Impact factor: 6.466

4.  Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.

Authors:  A L Feldman; M Law; E D Remstein; W R Macon; L A Erickson; K L Grogg; P J Kurtin; A Dogan
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.